EMA/182175/2014

European Medicines Agency decision

P/0122/2014

of 7 May 2014

on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant human alpha-mannosidase (EMEA-001056-PIP02-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0122/2014

of 7 May 2014

on the agreement of a paediatric investigation plan and on the granting of a deferral for recombinant human alpha-mannosidase (EMEA-001056-PIP02-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Zymenex on 10 December 2012 under Article 16(1) of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 21 March 2014, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for recombinant human alpha-mannosidase, powder for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for recombinant human alpha-mannosidase, powder for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Zymenex, 12C, Roskildevej, DK-3400 – Hillerød, Denmark.

Done at London, 7 May 2014

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/9656/2014

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMEA-001056-PIP02-12

Scope of the application

Active substance(s):

Recombinant human alpha-mannosidase

Condition(s):

Treatment of alpha-mannosidosis

Pharmaceutical form(s):

Powder for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Zymenex

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Zymenex submitted for agreement to the European Medicines Agency on 10 December 2012 an application for a paediatric investigation plan for the above mentioned medicinal product.

The procedure started on 16 January 2013.

Supplementary information was provided by the applicant on 20 December 2013. The applicant proposed modifications to the paediatric investigation plan and requested a deferral.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 21 March 2014

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

Not applicable

2. Paediatric Investigation Plan

2.1. Condition: treatment of alpha-mannosidosis

2.1.1. Indication(s) targeted by the PIP

Treatment of alpha-mannosidosis.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Powder for solution for infusion.

2.1.4. Measures

Area	Number of studies	Description
Quality - related studies	0	Not applicable.
Non-clinical studies	2	Study 1: CRL 495110 Preliminary juvenile toxicity study in rats, lasting up to 11 weeks. Study 2: CRL 495126 Main juvenile toxicity study in Sprague-Dawley rats, lasting 10 weeks.
Clinical studies	6	Study 3: rhLAMAN-01 Twenty four-month multicentre, prospective, observational study to evaluate parameters of relevance in untreated children (and adults) with alpha-mannosidosis. Study 4: rhLAMAN-02 Open-label, dose escalation study to evaluate pharmacokinetics and safety of intravenous recombinant human alpha-mannosidase in patients from 5 to 20 years of age with alpha-mannosidosis. Study 5: rhLAMAN-03 Six-month open-label, multiple dose study to evaluate efficacy and safety of intravenous recombinant human alpha-mannosidase in patients from 5 to 21 years of age with alpha-mannosidosis.

Area	Number of studies	Description
		Study 6: rhLAMAN-04 Six-month open-label, multiple dose study to evaluate efficacy and safety of intravenous recombinant human alpha-mannosidase in patients from 5 to 21 years of age with alpha-mannosidosis. Study 7: rhLAMAN-05 Twelve-month multi-centre, double blind, randomized, active/placebo study to evaluate the efficacy and safety of intravenous recombinant human alpha-mannosidase in patients from 5 to less than 36 years of age with alpha-mannosidosis. Study 8: rhLAMAN-08 Twenty four-month multi-centre, open label study to evaluate pharmacokinetics, safety and efficacy of intravenous recombinant human alpha-mannosidase in patients from birth to less than 6 years of age with alpha-mannosidosis.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By May 2020
Deferral for one or more measures contained in the paediatric investigation plan:	Yes